2000 – present

  1. 1.        Maclure M, Mittleman MA.  Should we use a case-crossover design?  Ann Rev Public Health 2000;21:193-221.
  2. 2.        Maclure M, Carleton B, Schneeweiss S. Effects and ethics of sanctions on childhood immunization rates. JAMA. 2000;284:2056-7
  3. 3.        Mukamal KJ, Muller JE, Maclure M, Sherwood JB, Mittleman MA.  Increased risk of congestive heart failure among infarctions with nighttime onset.  Am Heart J. 2000;140:438-42.
  4. 4.        Cher D, Maclure M.  Use of randomized controlled trials in organizational decision-making: a cost minimization approach.  Am J Manag Care 2000;6:894-904.
  5. 5.        Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 2000;29:891-8.
  6. 6.        Maclure M, Schneeweiss S.  Causation of bias: The Episcope.  Epidemiology 2001;12:114-22.
  7. 7.        Schneeweiss S, Maclure M, Walker AM, Grootendorst P, Soumerai SB: On the evaluation of drug policy changes with longitudinal claims data: The policy maker’s versus the clinician’s perspective. Health Policy 2001;55:97-109.
  8. 8.        Mukamal KJ, Maclure M, Sherwood JB, Kannam JP, Muller JE, Mittleman MA.  Height is not associated with long-term survival after acute myocardial infarction.  Am Heart J  2001;142:852-6.
  9. 9.        Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ.  Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.  Am J Epidemiol. 2001;154:854-64.
  10. 10.    Mukamal KJ, Muller JE, Maclure M, Sherwood JB, Mittleman MA.  Evaluation of sex-related differences in survival after hospitalization for acute myocardial infarction.  Am J Cardiol 2001;88:768-71.
  11. 11.    Mukamal KJ, Nesto RW, Cohen MC, Muller JE, Maclure M, Sherwood JB, Mittleman MA. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction.  Diabetes Care 2001;24:1422-7.
  12. 12.    Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana.  Circulation 2001;103:2805-9.
  13. 13.    Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA.  Prior alcohol consumption and mortality following acute myocardial infarction.  JAMA 2001;285:1965-70.
  14. 14.    Schneeweiss S, Maclure M, Soumerai SB: Prescription duration after drug copay changes in the elderly: Methodological aspects. J Am Geriatr Soc 2002;50:521-5.
  15. 15.    Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference drug pricing for angiotensin-converting enzyme inhibitors. N Engl J Med 2002;346:822-9.
  16. 16.    Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM: Impacts of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. J Can Med Assoc 2002;166:737-45.
  17. 17.    Mukamal KJ, Muller JE, Maclure M, Sherwood, JB, Mittleman MA. Variation in the risk of onset of acute myocardial infarction during the menstrual cycle.  Am J Cardiol 2002;90:49-51.
  18. 18.    Sondergaard J, Andersen M, Vach K, Kragstrup J, Maclure M, Gram LF.  Detailed postal feedback about prescribing to asthma patients combined with a guideline statement showed no impact: a randomised controlled trial. Eur J Clin Pharmacol 2002;58:127-32.
  19. 19.    Mukamal KJ, Maclure M, Muller JE, Sherwood, JB, Mittleman MA. Tea consumption and mortality following acute myocardial infarction.  Circulation 2002;105:2476-81.
  20. 20.    Schneeweiss S, Maclure M, Soumerai SB, Walker AM, Glynn RJ: Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. J Clin Epidemiol 2002;55:833-41.
  21. 21.    Mukamal KJ, Muller JE, Walkoff DS, Maclure M, Sherwood JB, Mittleman MA. Comparison of courses of patients with acute myocardial infarction with chest pain appearing during exertion versus those with chest pain not occurring during exertion.Am J Cardiol 2002;90:642-5
  22. 22.    Schneeweiss S, Maclure M, Dormuth C: On the evaluation of drug policy changes with longitudinal claims data: Concepts of income-based deductibles and issues related to causal inference. Dis Manage Health Outcomes 2002;10:763-9.
  23. 23.    Vinson DC, Maclure M, Reidinger C, Smith GS.  A population-based case-crossover and case-control study of alcohol and the risk of injury.  J Stud Alcohol 2003; 64:358-66.
  24. 24.    Duetz MS, Schneeweiss S, Maclure M, Abel T, Glynn RJ, Soumerai SB.  Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia. Clin Ther 2003;25:273-84. 
  25. 25.    Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ: Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharm Ther 2003;74:388-400
  26. 26.    Wakefield J, Herbert CP, Maclure M, Dormuth C, Wright JM, Legare J, Brett-MacLean P, Premi J. Commitment to change statements can predict actual change in practice. J Contin Educ Health Prof. 2003;23:81-93
  27. 27.    Lynd LD, Warren LD, Maclure M, Pare PD, Anis AH. Using administrative healthcare data to recruit study subjects: experience with ‘camouflaged sampling’. Eur J Epidemiol 2004;19:517-25.
  28. 28.    Falkoe E, Rasmussen KB, Maclure M, Schroll H.: Statistical linkage of treatment to diagnosis for research and monitoring of practice patterns. Methods Inf Med 2004;43:282-6.
  29. 29.    Eriksson T, Maclure M, Kragstrup J: Consultation with the general practitioner triggered by advice from social network members. Scand J Prim Health Care 2004;22:54-9.
  30. 30.    Schneeweiss S; Maclure M; Carleton B; Glynn R; Avorn J: Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. Br Med J 2004; 328:560-7
  31. 31.    Schneeweiss S, Wang PS, Avorn J, Maclure M, Levin R, Glynn RJ. Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. Utilization data.   J Gen Intern Med 2004;19:444-50.
  32. 32.    Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA. Educational attainment and myocardial infarct-related congestive heart failure (The Determinants of Myocardial Infarction Onset Study). Am J Cardiol. 2004 15;93:1288-91
  33. 33.    Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA. Caffeinated coffee consumption and mortality after acute myocardial infarction. Am Heart J 2004;147:999-1004.
  34. 34.    Schneeweiss S, Dormuth C, Grootendorst P, Maclure M.  Net health plan savings from reference drug pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care 2004;42:653-60.    
  35. 35.    Herbert CP, Wright JM, Maclure M, Wakefield J, Dormuth C, Brett-MacLean P, Legare J, Premi J.  Better Prescribing Project: a randomized controlled trial of the impact on prescribing of case-based educational modules and personal prescribing feedback.  Fam Pract 2004;21:575-81.
  36. 36.    Dormuth CR, Maclure M, Bassett K, Jauca C, Whiteside C, Wright JM.  Periodic letters on evidence-based drug therapy improves prescribing: a randomized trial. CMAJ 2004;171:1057-61.
  37. 37.    Eriksson T, Maclure M, Kragstrup J. To what extent do mass media health messages trigger patients’ contacts with their GPs?   Br J Gen Pract 2005;55:212-7.
  38. 38.    Mittleman MA, Maclure M, Glasser DB.  Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate.   Am J Cardiol. 2005;96:443-6.
  39. 39.    Maclure M.  Drug insurance utilization management policies and "reference pricing": an illustrated commentary on the article by Vittorio Maio and colleagues..  Milbank Q 2005; 83:131–47.
  40. 40.    Mukamal KJ, Maclure M, Muller JE, Mittleman MA.  Binge drinking and mortality after acute myocardial infarction.  Circulation. 2005;112:3839-45.
  41. 41.    Schneeweiss S, Maclure M, Dormuth CR, Glynn RJ, Canning C, Avorn J.  A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.  Clin Pharmacol Ther. 2006 ;79:379-88.
  42. 42.    Maclure M, Nguyen A, Carney G, Dormuth C, Roelants H, Ho K, Schneeweiss S. Measuring prescribing improvements in pragmatic trials of educational tools for general practitioners.  Basic Clin Pharmacol Toxicol. 2006;98:243-52.